GID4 and cancer: Although the regulatory mechanisms controlling GID4-mediated ARHGAP11A degradation under physiological conditions remain to be examined, we note that ARHGAP11A expression is increased in various cancers, including hepatocellular and clear cell renal carcinoma and gastric cancer.